2017 SCHEDULE COMING SOON...
12:00-2:15pm Panel Discussions: Pechet Room, NRB
Moderator: Pearl Freier, President, Cambridge BioPartners, Inc.
12:00-1:00pm Opportunities to Work on Breakthroughs in Cancer Immunotherapy and Gene Editing/CRISPR
World class leaders from three of biotech’s most exciting and innovative companies will share insights into their organizations, growth opportunities in the field, their approaches to building successful teams and hiring, the benefits and risks of working for biotech companies, and suggestions for transitioning from academia to industry. Panel discussion followed by Q&A with the audience.
Unum Therapeutics, Intellia Therapeutics, and Jounce Therapeutics are all well-financed biotech companies in Cambridge, MA working on the cutting edge of science, to bring new medicines to patients with critical unmet medical needs. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers. Intellia is a leading gene editing company focused on the development of proprietary therapeutics and potentially curative treatment using a recently developed biological tool known as the CRISPR/Cas9 system. CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Jounce's Translational Science Platform utilizes a suite of integrated technologies to profile the immune cellular and molecular characteristics within thousands of human solid tumors, providing critical information on the tumor micro-environment (TME) that allows them to identify and guide new immunotherapies more efficiently through development.
Seth Ettenberg, PhD, Chief Scientific Officer, Unum Therapeutics
Sriram Sathyanarayanan, PhD, Director of Translational Science, Jounce Therapeutics
Walter Strapps, PhD, Senior Director, Intellia Therapeutics
1:15-2:15pm Nontraditional Career Paths at World Class Companies for PhDs and Graduate Students Outside of the Bench
Join our chat with leaders at world class Boston area companies to discuss nontraditional career paths outside of the bench. We will explore opportunities in medical affairs, medical communications, healthcare, digital medicine, market strategy, video gaming, bioprocessing, and consulting services.
Akili Interactive was co-founded by Puretech, leading cognitive neuroscientists, and top-tier entertainment software creators to build clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like high quality video games. Akili’s partners include Pfizer and Shire Pharmaceticals and they are developing a technology platform that could detect brain disorders like attention deficit hyperactivity disorder (ADHD) and Alzheimer’s, as well as improve cognitive function. ARIAD Pharmaceuticals is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. In 2012, the FDA approved ARIAD's leukemia drug Iclusig for patients with all forms of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or unable to tolerate other tyrosine kinase therapies on the market. GE Healthcare Life Sciences provides expertise and tools for a wide range of applications, including basic research of cells and proteins, drug discovery research, as well as tools to support large-scale manufacturing of biopharmaceuticals.
Lorraine Attridge, U.S. Fast Trak Leader, GE Healthcare
Ashley Mateus, PhD, Director of Market Strategy, Akili Interactive
Ruth du Moulin, PhD, VP Medical Affairs Operations, ARIAD Pharmaceuticals
1:00-5:00pm Career Fair Recruiting Tables: Rotunda, NRB
Come and meet key recruitment personnel from industry leaders in the fields of pharma, biotech, consulting, medical communications, patent law, and more. Click here for a list of participating companies.
2:30-4:15pm Company Presentations: Pechet Room, NRB
2:50-3:10pm Safety Partners, Inc.
3:10-3:30pm C1 Consulting
3:35-3:55pm BGB Group
3:55-4:15pm Healthcare Consultancy Group
4:30-5:30pm Keynote: Pechet Room, NRB
Robert Langer, Sc.D.
Creating and implementing breakthrough technologies
Robert Langer is an Institute Professor at MIT (there are 13 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member). He has written more than 1,350 articles and has over 1,100 issued and pending patents worldwide. He is one of 4 living people to receive both the US National Medal of Science and the US National Medal of Technology and Innovation. He has also received the Charles Stark Draper Prize (considered the engineering Nobel Prize), the Albany Medical Center Prize and the Breakthrough Prize (largest US medical prizes), the Wolf Prize for Chemistry, the Kyoto Prize and the Lemelson-MIT Prize for being “one of history’s most prolific inventors in medicine.” Langer is one of the very few individuals ever elected to the National Academy of Medicine, the National Academy of Engineering and the National Academy of Sciences. He started over 30 companies including Enzytech (merged to become Alkermes), Moderna and Momenta and his patents have been licensed to over 300 companies. He is one of the 10 most cited individuals and the most cited engineer in history.